Penumbra, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 0P8.F | 5187.T | TUO.F | 2190.HK | 2160.HK | 0853.HK | |
|---|---|---|---|---|---|---|
| Market cap | 11.30B | 8.84B | 21.09B | 6.45B | 1.63B | 11.62B |
| P/E (TTM) | 84.1 | 18.2 | 23.1 | 18.3 | — | — |
| Forward P/E | 180.4 | — | — | 11.4 | 37.9 | 23.3 |
| Price/book | 8.0 | 0.5 | 2.3 | 1.9 | 0.8 | 1.5 |
| Dividend yield | — | 4.33% | 1.53% | 1.30% | — | — |
| 1-year change | +46.08% | +10.47% | −5.14% | −18.44% | −77.54% | −46.33% |
| Today | 0.00% | +0.27% | +8.79% | +1.19% | 0.00% | 0.00% |
The closest companies by business and industry (Medical Devices). Prices may be delayed up to 20 min.
Latest news
All 0P8.F news ›Penumbra (NYSE:PEN) Announces Quarterly Earnings Results
Posted by Michael Walen on Oct 31st, 2026 Get Our Latest Research Report on Penumbra Penumbra, Inc is a medical device company that develops, manufactures and markets products used to treat patients with vascular conditions. Its…
Penumbra, Inc. Reports Third Quarter 2026 Financial Results
ALAMEDA, Calif., Oct. 29, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2026. Full Year 2026 Financial Outlook and…
Penumbra GAAP EPS of $1.07 misses by $0.11, revenue of $410.1M beats by $7.73M
Penumbra Q3 results: EPS missed, but revenue beat with 15.6% growth and strong thrombectomy sales. - Penumbra press release (PEN): Q3 GAAP EPS of $1.07 misses by $0.11. - Revenue of $410.1M (+15.6% Y/Y) beats by $7.73M. - Global…
Overturning Common Sense in Stroke and Acute Care: Does 'Hasty Lowering' of High Blood Pressure Kill Brain Cells? The Science of 'Permissive Hypertension' (220/120 Rule) to Save the Penumbra and Orthostatic Hypotension During Mobilization
"The blood pressure of a patient admitted for acute ischemic stroke is 180/100 mmHg! It's dangerous if they have a recurrence or cerebral hemorrhage, so we should immediately lower it to normal levels (below 130) with antihypertensive…
Penumbra’s CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)
BOLT-DVT, a recent prospective, multicenter Investigational Device Exemption (IDE) trial, demonstrated first-line use of computer assisted vacuum thrombectomy Penumbra’s CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein…
Comparing Neogen (NASDAQ:NEOG) & Penumbra (NYSE:PEN)
Posted by Defense World Staff on Oct 19th, 2026 Neogen (NASDAQ:NEOG – Get Free Report) and Penumbra (NYSE:PEN – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based…
Penumbra (NYSE:PEN) Stock Breaks Above 50-Day Moving Average – Should You Sell?
Posted by Defense World Staff on Oct 17th, 2026 Penumbra, Inc. (NYSE:PEN – Get Free Report)’s share price passed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $321.17 and traded as…
Penumbra Mezcal Launches
www.marketwatchmag.com Foley Family Wine & Spirits has launched Penumbra mezcal, the first agave-based spirit developed by Chip Tate, Foleyâs master distiller of innovation The mezcal ($45 a 750-ml.) is distilled from EspadÃn and…
Could STORM-PE Data Change Penumbra (NASDAQ:PEN) Story?
The six-minute walk test remains an established functional assessment used to evaluate exercise capacity. Comparing wearable measurements with such clinical assessments can provide information about how digital activity data relates to…
Tranche Update on Penumbra, Inc.'s Equity Buyback Plan announced on August 13, 2024.
From April 1, 2026 to June 30, 2026, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 517,763 shares, representing 1.33% for... Published on 07/30/2026 at 04:45 pm…
From the 4Search news index, newest first.